Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.45 |
| ▸ | PNMT | P11086 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3438629 | 0.83 | TAAR1 (0.47) | TAAR1TP53IDO1PNMTSLC6A2 | |
| SCHEMBL3814505 | 0.83 | MEN1 (0.50) | TAAR1IDO1PNMTSLC6A2SLC6A4 | |
| SCHEMBL3357458 | 0.83 | CALM1 (0.55) | TAAR1IDO1PNMTMEN1KMT2A | |
| SCHEMBL4423210 | 0.82 | SIGMAR1 (0.53) | TAAR1IDO1PNMTMEN1KMT2A | |
| SCHEMBL22852737 | 0.82 | TAAR1 (0.50) | TAAR1TP53IDO1PNMTSLC6A2 | |
| SCHEMBL3622807 | 0.80 | MEN1 (0.66) | SLC5A1SLC5A2MEN1KMT2A | |
| SCHEMBL8752818 | 0.79 | SMN1; SMN2 (0.47) | TAAR1IDO1PNMT | |
| SCHEMBL21186239 | 0.79 | ALDH1A1 (0.52) | TAAR1IDO1PNMT | |
| SCHEMBL2089904 | 0.79 | KDM4E (0.53) | TAAR1TP53IDO1PNMTSLC6A2 | |
| SCHEMBL6299177 | 0.79 | KEAP1 (0.64) | TP53IDO1PNMTSLC5A1SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589193-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SEED, BRIAN | 2009-06-18 | — | — | US | disclosed |
| WO-2009076550-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| EP-1791852-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156516-A1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | SLC5A2, SLC5A1, SLC2A8 | TAAR1 3234/4885TP53 4848/4885IDO1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.